Overview

Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained. The study was terminated when all ongoing participants had been treated for at least 5 years.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Ferring Pharmaceuticals